Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
|Videos|September 5, 2021
Advantages of transperineal biopsies over transrectal biopsies
Author(s)Urology Times staff
Advertisement
In this video, Matthew J. Allaway, MD, assesses the differences between the transrectal and transperineal approaches to prostate biopsy and the overall advantage of the transperineal biopsy in detecting cancer and preventing infection. Allaway is the founder and president of Perinealogic, and a urologist and managing partner at Urology Associates, Cumberland, Maryland.
Advertisement
Related to this article
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
Infertility care: Examining geographic gaps in access
3
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
4
Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide
5